TY  - CONF

T1  - An updated cost-effectiveness analysis of evolocumab therapy for reducing cardiovascular events in very high-risk patients with atherosclerotic cardiovascular disease according to the 2018 ACC/AHA guideline

JO  - Journal of Clinical Lipidology

PY  - 2019/05/26

AU  - Fonarow GC

AU  - van Hout B

AU  - Villa G

AU  - Arellano J

AU  - Lindgren P

ED  - 

DO  - DOI: 10.1016/j.jacl.2019.04.054

PB  - Elsevier BV

VL  - 13

IS  - 3

SP  - e31

EP  - e31

Y2  - 2024/12/22

ER  -